{
    "eid": "2-s2.0-85030610268",
    "title": "Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents",
    "cover-date": "2017-10-01",
    "subject-areas": [
        {
            "$": "Microbiology (medical)",
            "@code": "2726"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Pediatrics",
            "@code": "2735"
        }
    ],
    "keywords": [
        "adolescents",
        "outcomes",
        "Thai",
        "third-line antiretroviral regimen"
    ],
    "authors": [
        "Wasana Prasitsuebsai"
    ],
    "citedby-count": 8,
    "ref-count": 38,
    "ref-list": [
        "UNAIDS. Un Joint Programme on HIV/AIDS (UNAIDS): The Gap Report 2014",
        "The 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015)",
        "Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children",
        "Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic",
        "Pediatric Response to Second-Line Antiretroviral Therapy in South Africa",
        "Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents",
        "Predictors of treatment failure in hiv-positive children receiving combination antiretroviral therapy: Cohort data from Mozambique and Uganda",
        "Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens among Asian Children",
        "Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy",
        "Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial",
        "Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial",
        "Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial",
        "Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study",
        "Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study",
        "Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: Week 48 results of the ARIEL trial",
        "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years",
        "Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents : Forty-eight-week results from IMPAACT P1093",
        "Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus",
        "World Health Organization (WHO). Global Price Reporting Mechanism",
        "The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand",
        "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand",
        "The 7th International Workshop on HIV Pediatrics",
        "2014 update of the drug resistance mutations in HIV-1",
        "U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0. [Updated August 2009]",
        "Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies",
        "Long-term outcome of second-line antiretroviral therapy in resource-limited settings",
        "Use of third line antiretroviral therapy in Latin America",
        "Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India",
        "Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience",
        "Raltegravir, etravirine, and ritonavir-boosted darunavir: A safe and successful rescue regimen for multidrug-resistant HIV-1 infection",
        "Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE study",
        "Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents",
        "Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents",
        "Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States",
        "Comparison of HIV Virologic Failure Rates between Patients with Variable Adherence to Three Antiretroviral Regimen Types",
        "Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial",
        "Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV",
        "Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral Therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Amsterdam",
            "affilname": "Universiteit van Amsterdam",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Thai Red Cross Agency",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Nakornping Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Prapokklao Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "affilname": "The Kirby Institute",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": null,
            "affilname": "Surin Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "affilname": "Khon Kaen University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine Siriraj Hospital, Mahidol University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "affilname": "Bamrasnaradura Infectious Diseases Institute",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiang Rai",
            "affilname": "Chiangrai Prachanukroh Hospital",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Ministry of Edu-cation"
    ]
}